Perception, Practice, and Attitude Toward Prostate-specific Antigen Test Among Sudanese Urologists


Background: The introduction of prostate-specific antigen (PSA) has revolutionized the diagnosis of prostate cancer (PC). However, there is a wide variation in the daily practice of PSA testing with ongoing efforts to increase its sensitivity. This study aims to evaluate the attitude of Sudanese urologists toward the PSA test in their daily practice.

Methods: An online questionnaire was formed and sent to the academic group of Sudanese urologists; it was left for two months with weekly reminders. The group contains 135 members. Data were then collected and analyzed.

Results: Of the 135 members, 83 (61.5%) responded to the questionnaire, all were males, with 43% of them being consultants, and 37% having an experience between 5 and 10 years. Most participants (85%) use the test according to international guidelines, the majority (60%) counsel patients before the test, with 72% finding the test more than 50% reliable. In addition, >33% face problems when requesting PSA with >29% of them finding it unreliable. Moreover, in >13%, the test is unavailable. Nearly all participants (95%) think that there is a need for national guidelines to regulate the use of PSA tests.

Conclusion: For the diversity of practice toward the PSA test and the unavailability of adjunct methods that increase its sensitivity, there is a need for national guidelines to regulate the use of the test in the context of other clinical factors.


attitude, prostate cancer, prostate specific antigen, Sudanese urologists

[1] Kappen, S., Jürgens, V., Freitag, M. H., & Winter, A. (2021). Attitudes toward and use of prostate-specific antigen testing among urologists and general practitioners in Germany: A survey. Frontiers in Oncology, 11, 691197.

[2] Yeboah-Asiamah, B., Yirenya-Tawiah, D., Baafi, D., & Ackumey, M. M. (2017). Perceptions and knowledge about prostate cancer and attitudes towards prostate cancer screening among male teachers in the Sunyani Municipality, Ghana. African Journal of Urology, 23(3), 184–191.

[3] Jalali, A., Foley, R. W., Maweni, R. M., Murphy, K., Lundon, D. J., Lynch, T., Power, R., O’Brien, F., O’Malley, K. J., Galvin, D. J., Durkan, G. C., Murphy, T. B., & Watson, R. W. (2020). A risk calculator to inform the need for a prostate biopsy: A rapid access clinic cohort. BMC Medical Informatics and Decision Making, 20(1), 148.

[4] Gomez Gomez, E., Salamanca Bustos, J. J., Carrasco Valiente, J., Fernandez Rueda, J. L., Blanca, A., Valero Rosa, J., Bravo Arrebola, I., Marquez López, J., Jimenez Vacas, J. M., Luque, R., & Requena Tapia, M. J. (2019). Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mL. BMJ Open, 9(11), e031032.

[5] Tikkinen, K. A. O., Dahm, P., Lytvyn, L., Heen, A. F., Vernooij, R. W. M., Siemieniuk, R. A. C., Wheeler, R., Vaughan, B., Fobuzi, A. C., Blanker, M. H., Junod, N., Sommer, J., Stirnemann, J., Yoshimura, M., Auer, R., MacDonald, H., Guyatt, G., Vandvik, P. O., & Agoritsas, T. (2018). Prostate cancer screening with prostate-specific antigen (PSA) test: A clinical practice guideline. BMJ, 362, k3581.

[6] Kappen, S., Koops, L., Jürgens, V., Freitag, M. H., Blanker, M. H., Timmer, A., & de Bock, G. H. (2020). General practitioners’ approaches to prostate-specific antigen testing in the north-east of the Netherlands. BMC Family Practice, 21(1), 270.

[7] Hayat Roshanai, A., Nordin, K., & Berglund, G. (2013). Factors influencing primary care physicians’ decision to order prostate-specific antigen (PSA) test for men without prostate cancer. Acta Oncologica, 52(8), 1602–1608.

[8] Tun Firzara, A. M., & Ng, C. J. (2016). Knowledge and practice of prostate cancer screening among general practitioners in Malaysia: A cross-sectional study. BMJ Open, 6(9), e011467.

[9] Pickles, K., Carter, S. M., & Rychetnik, L. (2015). Doctors’ approaches to PSA testing and overdiagnosis in primary healthcare: A qualitative study. BMJ Open, 5(3), e006367–e006367.

[10] Akerman, J. P., Allard, C. B., Tajzler, C., & Kapoor, A. (2018). Prostate cancer screening among family physicians in Ontario: An update on attitudes and current practice. Canadian Urological Association Journal, 12(2), E53–E58.

[11] Thurtle, D. R., Gordon, E. M., Brierly, R. D., Conway, C. J., & McLoughlin, J. (2018). General practitioner perception of prostate-specific antigen testing has improved, but more awareness of prostate cancer risk in younger patients is still awaited. Prostate International, 6(2), 61–65.

[12] Rezaee, M. E., Ward, C. E., Sverrisson, E. F., & Dagrosa, L. M. (2019). Brief report: Impact of healthcare quality on prostate specific antigen screening for the early detection of prostate cancer. Preventive Medicine Reports, 14, 100838.

[13] Lamplugh, M., Gilmore, P., Quinlan, T., & Cornford, P. (2006). PSA testing: Are patients aware of what lies ahead? Annals of the Royal College of Surgeons of England, 88(3), 284–288.

[14] Nordström, T., Engel, J. C., Bergman, M., Egevad, L., Aly, M., Eklund, M., Palsdottir, T., & Grönberg, H. (2021). Identifying prostate cancer among men with lower urinary tract symptoms. European Urology Open Science, 24, 11–16.

[15] Brett, J., Watson, E., Hewitson, P., Bukach, C., Edwards, A., Elwyn, G., & Austoker, J. (2005). PSA testing for prostate cancer: An online survey of the views and reported practice of General Practitioners in the UK. BMC Family Practice, 6(1), 24.

[16] Godtman, R. A., Kollberg, K. S., Pihl, C.-G., Månsson, M., & Hugosson, J. (2022). The association between age, prostate cancer risk, and higher gleason score in a longterm screening program: Results from the Göteborg-1 Prostate Cancer Screening Trial. European Urology, 82, 311–317.

[17] Rendon, R. A., Mason, R. J., Marzouk, K., Finelli, A., Saad, F., So, A., Violette, P. D., & Breau, R. H. (2017). Canadian Urological Association recommendations on prostate cancer screening and early diagnosis. Canadian Urological Association Journal, 11(10), 298–309.

[18] Byun, H. J., Shin, T. J., Jung, W., Ha, J. Y., Kim, B. H., & Kim, Y. H. (2021). The value of magnetic resonance imaging and ultrasonography (MRI/US)-fusion biopsy in clinically significant prostate cancer detection in patients with biopsynaïve men according to PSA levels: A propensity score matching analysis. Prostate International.

[19] Grossman, D. C., Curry, S. J., Owens, D. K., Bibbins-Domingo, K., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Ebell, M., Epling, J. W., Jr., Kemper, A. R., Krist, A. H., Kubik, M., Landefeld, C. S., Mangione, C. M., Silverstein, M., Simon, M. A., Siu, A. L., Tseng, C. W., & the US Preventive Services Task Force. (2018). Screening for prostate cancer: US preventive services task force recommendation statement. Journal of the American Medical Association, 319(18), 1901–1913.

[20] Dejous, C., & Krishnan, U. M. Sensors for diagnosis of prostate cancer: Looking beyond the prostate specific antigen. Vol. 173, Biosensors and Bioelectronics. Elsevier Ltd; 2021.

[21] Bandala-Jacques, A., Castellanos Esquivel, K. D., Pérez-Hurtado, F., Hernández-Silva, C., & Reynoso-Noverón, N. (2021). Prostate Cancer risk calculators for healthy populations: Systematic review. JMIR Cancer, 7(3), e30430.